Close Menu


The bill would provide $4.5 billion from 2022 to 2026 to support clinical lab infrastructure to improve SARS-CoV-2 and COVID-19 testing and response.

The organization also supported the recommendation to include $1.75 billion in funding for the US Centers for Disease Control and Prevention.

While some remain concerned that the bill will reduce labs' leverage with payors, provisions like the use of arbitration for disputes are a win for providers.

The move raises questions about what precisely is an LDT outside of FDA jurisdiction and heightens concerns that poorly validated tests will enter the market and endanger public health.

Saying pooled testing for coronavirus was not for diagnostic purposes, Cigna had said it wouldn't reimburse for the method, but it plans to change its policy.

The funding package earmarks billions for the Public Health and Social Services Emergency Fund and Biomedical Advanced Research and Development Authority.

Issued last week, the guidance said insurers were not required to reimburse such testing, which could impact coverage in schools, workplaces, and other settings.

The Energy and Commerce Committee chairman asked the agency to show Congress all of the state and local plans for COVID-19 testing by July 6.

The experts said that antibody testing cannot indicate an individual's immunity or help with return-to-work schemes but have use for public health agencies.

The lawmakers requested the secretary to direct money from the Public Health and Social Services Emergency Fund to support clinical labs.